Gamida Cell Announces Launch of Public Offering of Ordinary Shares
September 27 2022 - 4:06PM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the
development of NAM-enabled cell therapies for patients with
hematologic and solid cancers and other serious diseases, today
announced the launch of a follow-on public offering of its ordinary
shares. In addition, Gamida Cell expects to grant the underwriters
a 30-day option to purchase up to an additional 15% of the ordinary
shares to be sold in the offering on the same terms and conditions.
The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be
completed. All of the shares in the offering are to be sold by
Gamida Cell.
Gamida Cell intends to use the net proceeds from this offering,
together with its existing cash and cash equivalents and trading
financial assets: to fund (i) commercial readiness activities to
support potential launch of omidubicel, if approved; (ii) the
continued clinical development of its NK product candidates,
including GDA-201; and (iii) general corporate purposes, including
general and administrative expenses and working capital.
Piper Sandler & Co. and JMP Securities, a Citizens Company,
are acting as joint book-running managers for this offering.
A registration statement on Form S-3 (File No. 333-259472)
relating to the ordinary shares has been filed with the Securities
and Exchange Commission and declared effective on April 1, 2022.
This offering will be made only by means of a prospectus
supplement. Copies of the preliminary prospectus supplement and the
accompanying prospectus related to this offering may be obtained,
when available, from: Piper Sandler & Co., 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924 or by email at
prospectus@psc.com, or JMP Securities LLC, 600 Montgomery Street,
Suite 1100, San Francisco, California 94111, Attention: Prospectus
Department, by calling (415) 835-8985, or by e-mail at
syndicate@jmpsecurities.com. Investors may also obtain these
documents at no cost by visiting the SEC’s website at
http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of
potentially curative cell therapy candidates for patients with
solid tumor and blood cancers and other serious blood diseases. We
apply a proprietary expansion platform leveraging the properties of
NAM to allogeneic cell sources including umbilical cord
blood-derived cells and NK cells to create therapy candidates with
potential to redefine standards of care. These include omidubicel,
an investigational product with potential as a life-saving
alternative for patients in need of bone marrow transplant, and a
line of modified and unmodified NAM-enabled NK cells targeted at
solid tumor and hematological malignancies.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to whether Gamida Cell will offer the
ordinary shares or consummate the offering, timing, size and use of
proceeds of the offering described herein, and its expectations
with respect to granting the underwriters a 30-day option to
purchase additional ordinary shares. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those that are described in the Risk Factors
sections of the preliminary prospectus supplement for such offering
to be filed with the SEC, and the documents incorporated by
reference therein, including without limitation the Company’s
Quarterly Report on Form 10-Q filed with the SEC on August 15,
2022, the accompanying prospectus and other filings that Gamida
Cell makes with the SEC from time to time (which are available at
http://www.sec.gov), any of which could cause the events and
circumstances discussed in such forward-looking statements to not
occur on the terms described or at all. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date hereof. Gamida Cell
undertakes no obligation to update any such forward-looking
statements after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220927006078/en/
Investor Contact: Courtney Turiano Stern Investor
Relations, Inc. Courtney.Turiano@sternir.com 1-212-362-1200
Media Inquiries: Heather DiVecchia Director, IR and
Corporate Communications Heather@gamida-cell.com 1-617-892-9083
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Sep 2023 to Sep 2024